Stephan Siegel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stephan Siegel has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Daniel Korr
Nuvisan ICB GmbH, Berlin, Germany
16 shared publications - Andrew D. Cherniack
Broad Institute of MIT and Harvard, Cambridge, MA, USA
15 shared publications - Bethany Kaplan
Broad Institute of MIT and Harvard 1 Cancer Program Cambridge, Massachusetts
15 shared publications - Daniel Denney
Broad Institute of MIT and Harvard 1 Cancer Program Cambridge, Massachusetts
15 shared publications - Dominik Rüttinger
Bayer AG, Pharmaceuticals, Research & Early Development Oncology, Berlin, Germany
15 shared publications - Franziska Siegel
Bayer AG, Pharmaceuticals, Research & Early Development Oncology, Berlin, Germany
15 shared publications
Latest Publications
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 Exon 20 insertion mutations
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antiproliferative activity of sevabertinib and EGFR/HER2 tyrosine kinase inhibitors in Ba/F3 cell lines with HER2 Exon 20 insertion mutations
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
The binding mode of sevabertinib within the ATP binding site of wild-type EGFR from two different views
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
The binding mode of sevabertinib within the ATP binding site of wild-type EGFR from two different views
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antitumor efficacy of sevabertinib in the subcutaneous CTG-2543 xenografts
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Antitumor efficacy of sevabertinib in the subcutaneous CTG-2543 xenografts
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib response and sensitivity to ERBB family gene CRISPR knockout or RNAi knockdown
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib response and sensitivity to ERBB family gene CRISPR knockout or RNAi knockdown
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Biochemical kinase activity of sevabertinib in ERBB and non-ERBB family kinases
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Biochemical kinase activity of sevabertinib in ERBB and non-ERBB family kinases
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
NRG1 fusions in cancer cell lines
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
NRG1 fusions in cancer cell lines
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib inhibition in KinaseProfiler kinase activity platform
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Sevabertinib inhibition in KinaseProfiler kinase activity platform
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Supplementary Methods: Crystal Structure Determination of Wild-Type EGFR in Complex with Sevabertinib. Xenograft models
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Supplementary Methods: Crystal Structure Determination of Wild-Type EGFR in Complex with Sevabertinib. Xenograft models
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Kinase inhibition of sevabertinib (1 μM) measured in the presence of 10 μM ATP
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Kinase inhibition of sevabertinib (1 μM) measured in the presence of 10 μM ATP
- Open Access
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Additional cell viability data of zongertinib and STX-721 in isogenic Ba/F3 cell lines
- 12 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Sevabertinib, a Reversible HER2 Inhibitor with Activity in Lung Cancer
Additional cell viability data of zongertinib and STX-721 in isogenic Ba/F3 cell lines